NCT05676450

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 517 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.

Detailed description

Primary Objective: • To determine the feasibility and clinical utility of ctDNA in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas. Secondary Objectives: * To provide useful prognostic information before treatment, assess molecular response at interim time points and residual disease at the end of therapy, and identify tumor-specific mutations * Levels of cfDNA and its association with both EFS and OS in patients receiving therapy

Conditions

• Lymphoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	cell-free DNA	Given by IV (vein)

Timeline

• Start date: 2023-02-23
• Primary completion: 2026-08-31
• Completion: 2026-08-31
• First posted: 2023-01-09
• Last updated: 2025-10-31

Locations

2 sites across 1 country: United States